![]() |
VOOZH | about |
Influenza, one of the most common infectious diseases, is a highly contagious airborne disease that occurs in seasonal epidemics and manifests as an acute febrile illness with variable degrees of systemic symptoms, ranging from mild fatigue to respiratory failure and death. Influenza causes significant loss of workdays, human suffering, and mortality.
Although the seasonal strains of influenza virus that circulate in the annual influenza cycle constitute a substantial public health concern, far more lethal influenza strains than these have emerged periodically. These deadly strains produced three global pandemics in the last century, the worst of which occurred in 1918. Called the Spanish flu (though cases appeared earlier in the United States and elsewhere in Europe), this pandemic killed an estimated 20 to 50 million persons, with 549,000 deaths in the United States alone. [1]
Influenza also infects a variety of animal species. Some of these influenza strains are species-specific, but new strains may spread from other animals to humans (see Pathophysiology). The term avian influenza, in this context, refers to zoonotic human infection with an influenza strain that primarily affects birds. Swine influenza refers to infections from strains derived from pigs. The 2009 influenza pandemic was a recombinant influenza involving a mix of swine, avian, and human gene segments (see H1N1 Influenza [Swine Flu]).
The signs and symptoms of influenza overlap with those of many other viral upper respiratory tract infections (URIs). A number of viruses, including human parainfluenza virus, adenoviruses, enteroviruses, and paramyxoviruses, may initially cause influenzalike illness. The early presentation of mild or moderate cases of flavivirus infections (eg, dengue) may initially mimic influenza. For example, some cases of West Nile fever acquired in New York in 1999 were clinically misdiagnosed as influenza. [2]
When influenza viruses are circulating in the community, clinicians can often diagnose influenza on the basis of clinical criteria alone (see Presentation). Rapid diagnostic tests for influenza that can provide results within 30 minutes can help confirm the diagnosis.
It should be kept in mind, however, that these rapid tests have limited sensitivities and predictive values; false-negative results are common, especially when influenza activity is high, and false-positive results can also occur, especially when influenza activity is low. [3] Nevertheless, influenza virus testing may be considered if the results will change the clinical care of the patient (especially if the patient is hospitalized or has a high-risk condition) or influence the care of other patients. [3]
The gold standard for confirming influenza virus infection is reverse transcription-polymerase chain reaction (RT-PCR) testing or viral culture of nasopharyngeal or throat secretions. However, culture may require 3 to 7 days, yielding results long after the patient has left the clinic, office, or emergency department, and well past the time when drug therapy could be efficacious.
Prevention of influenza is the most effective strategy. Each year in the United States, a vaccine that contains antigens from the strains most likely to cause infection during the winter flu season is produced. The vaccine provides reasonable protection against immunized strains, becoming effective 10 to 14 days after administration. Antiviral agents are also available that can prevent some cases of influenza; when given after the development of influenza, they can reduce the duration and severity of illness.
For information on influenza in children, see Pediatric Influenza.
Influenza results from infection with one of three basic types of influenza virus: A, B, or C. Influenza A is generally more pathogenic than influenza B. Epidemics of influenza C have been reported, especially in young children. [13] Influenza viruses are classified within the family Orthomyxoviridae.
In the United States, influenza A(H3N2) was the predominant strain during the 2021-2022 flu season.
Avian influenza (ie, human infection with avian H5N1 influenza virus) is transmitted primarily through direct contact with diseased or deceased birds infected with the virus. Contact with excrement from infected birds or contaminated surfaces or water are also considered mechanisms of infection. Close and prolonged contact of a caregiver with an infected person is believed to have resulted in at least one case. Other specific risk factors are not apparent, given the few cases to date.
Influenza viruses are enveloped, negative-sense, single-stranded RNA viruses of the family Orthomyxoviridae. The core nucleoproteins are used to distinguish the three types of influenza viruses: A, B, and C. Influenza A viruses cause most human and all avian influenza infections. The RNA core consists of eight gene segments surrounded by a coat of 10 (influenza A) or 11 (influenza B) proteins. Immunologically, the most significant surface proteins include hemagglutinin (H) and neuraminidase (N).
Hemagglutinin and neuraminidase are critical for virulence, and they are major targets for the neutralizing antibodies of acquired immunity to influenza. Hemagglutinin binds to respiratory epithelial cells, allowing cellular infection. Neuraminidase cleaves the bond that holds newly replicated virions to the cell surface, permitting the infection to spread. [4]
Major typing of influenza A occurs through identification of both H and N proteins. Seventeen H and nine N types have been identified. All hemagglutinins and neuraminidases infect wild waterfowl, and the various combinations of H and N yield 144 potential subtypes of influenza.
The hemagglutinin and neuraminidase variants are used to identify influenza A virus subtypes. For example, influenza A subtype H3N2 expresses hemagglutinin 3 and neuraminidase 2. The most common subtypes of human influenza virus identified to date contain only hemagglutinins 1, 2, and 3 and neuraminidases 1 and 2. H3N2 and H1N1 are the most common prevailing influenza A subtypes that infect humans. Each year, the trivalent vaccine used worldwide contains influenza A strains from H1N1 and H3N2, along with an influenza B strain. The quadrivalent vaccine contains an additional influenza B strain.
Because the viral RNA polymerase lacks error-checking mechanisms, the year-to-year antigenic drift is sufficient to ensure that there is a significant susceptible host population each year. However, the segmented genome also has the potential to allow reassortment of genome segments from different strains of influenza in a coinfected host.
Influenza A is a genetically labile virus, with mutation rates as high as 300 times that of other microbes. [5] Changes in its major functional and antigenic proteins occur by means of two well-described mechanisms: antigenic drift and antigenic shift.
Antigenic drift is the process by which inaccurate viral RNA polymerase frequently produces point mutations in certain error-prone regions in the genes. These mutations are ongoing, and they are responsible for the ability of the virus to evade annually acquired immunity in humans. Drift can also alter the virulence of the strain. Drift occurs within a set subtype (eg, H2N2). For example, AH2N2 Singapore 225/99 may reappear with a slightly altered antigen coat as AH2N2 New Delhi 033/01.
Antigenic shift is less frequent than antigenic drift. In a shift event, influenza genes between two strains are reassorted, presumably during coinfection of a single host. Segmentation of the viral genome, which consists of 10 genes on eight RNA molecules, facilitates genetic reassortment. Because pigs have been susceptible to both human and avian influenza strains, many experts believe that combined swine and duck farms in some parts of Asia may have facilitated antigenic shifts and the evolution of previous pandemic influenza strains.
The reassortment of an avian strain with a mammalian strain may produce a chimeric virus that is transmissible between mammals; such mutation products may contain H or N proteins that are unrecognizable to the immune systems of mammals. This antigenic shift results in a much greater population of susceptible individuals in whom more severe disease is possible.
Such an antigenic shift can result in a virulent strain of influenza that possesses the triad of infectivity, lethality, and transmissibility and can cause a pandemic. Three major influenza pandemics have been recorded:
Smaller outbreaks occurred in 1947, 1976, 1977, and 2009.
Transmission of influenza from poultry or pigs to humans appears to occur predominantly as a result of direct contact with infected animals. The risk is especially high during slaughter and preparation for consumption; eating properly cooked meat poses no risk. Avian influenza can also be spread through exposure to water and surfaces contaminated by bird droppings. [6]
Influenza viruses spread from human to human via aerosols created when an infected individual coughs or sneezes. Infection occurs after an immunologically susceptible person inhales the aerosol. If not neutralized by secretory antibodies, the virus invades airway and respiratory tract cells.
On April 18, 2024, the World Health Organization (WHO) published a global technical consultation report that introduced updated terminology for pathogens that are transmitted through the air. These include those that cause COVID-19, influenza, measles, Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), and tuberculosis.
During 2021-2023, the WHO collaborated with experts from various disciplines and specialties as well as Africa Centres for Disease Control and Prevention; Chinese Center for Disease Control and Prevention; European Centre for Disease Prevention and Control; and United States Centers for Disease Control and Prevention. [7]
Their work “addressed a lack of common terminology” regarding transmission of pathogens through the air that highlighted issues associated with the term “airborne transmission.”
The groups reached consensus on the term ‘infectious respiratory particles,’ which describes pathogens of various particle sizes that can be spread through the air at short and long ranges. “Transmission through the air” may be used as an umbrella term to describe spread of IRPs through the air by either airborne transmission or direct deposition modes.
Once the virus is within host cells, cellular dysfunction and degeneration occur, along with viral replication and release of viral progeny. As in other viral infections, systemic symptoms result from release of inflammatory mediators.
The incubation period of influenza ranges from 1 to 4 days. Aerosol transmission may occur 1 day before the onset of symptoms [8] ; thus, it may be possible for transmission to occur via asymptomatic persons or persons with subclinical disease, who may be unaware that they have been exposed to the disease. [2, 9, 10]
Viral shedding occurs at the onset of symptoms or just before the onset of illness (0-24 hours) and continues for 5 to 10 days. Young children may shed virus longer, placing others at risk of contracting infection. In highly immunocompromised persons, shedding may persist for weeks to months. [10]
To date, avian influenza (H5) remains a zoonosis. The vast majority of cases of avian influenza have been acquired from direct contact with live poultry, with no sustained human-to-human transmission. Hemagglutinin type 5 attaches well to avian respiratory cells and thus spreads easily among avian species. However, attachment to human cells and resultant infection is more difficult.
Avian viruses tend to prefer sialic acid alpha(2-3) galactose, which, in humans, is found in the terminal bronchi and alveoli. Conversely, human viruses prefer sialic acid alpha(2-6) galactose, which is found on epithelial cells in the upper respiratory tract. [11] Although this results in a more severe respiratory infection, it probably explains why few, if any, definite human-to-human transmissions of avian influenza have been reported: infection of the upper airways is probably required for efficient spread via coughing and sneezing.
Most human deaths from bird flu have occurred in Indonesia. Sporadic outbreaks among humans have continued elsewhere, including China, Egypt, Thailand, and Cambodia. [12]
In theory, however, mutation of the hemagglutinin protein through antigenic drift could result in a virus capable of binding to upper and lower respiratory epithelium, creating a strain that is easily transferred from human to human and thus could cause a worldwide pandemic.
In tropical areas, influenza occurs throughout the year. In the Northern Hemisphere, the influenza season typically starts in early fall, peaks in mid-February of the following year, and ends in the late spring. The duration and severity of influenza epidemics vary, however, depending on the virus subtype involved.
The WHO estimates that 1 billion influenza cases, 3 to 5 million severe cases, and 290,000 to 650,000 influenza-related respiratory deaths occur each year worldwide. [14] In the United States, individual cases of seasonal flu and flu-related deaths in adults are not reportable illnesses; consequently, mortality is estimated by using statistical models. [15]
The CDC estimates that flu-associated deaths in the United States ranged from about 3000 to 49,000 annually between 1976 and 2006. The CDC notes that the often-cited figure of 36,000 annual flu-related deaths was derived from years when the predominant virus subtype was H3N2, which tends to be more lethal than H1N1. [15]
Unlike adult flu-related deaths, pediatric flu-related deaths are reportable in the United States. (See Pediatric Influenza.) For the 2019-2020 influenza season, the CDC reports an estimated 35 million influenza-associated illnesses, 16 million influenza-related medical visits, 380,000 flu-associated hospitalizations, and 20,000 influenza-related deaths. A total of 486 children aged 0 months to 17 years died during the 2019-2020 influenza season. [15]
The following statistics are offered for comparison:
In contrast to typical influenza seasons, the 2009-2010 influenza season was affected by the H1N1 (“swine flu”) influenza epidemic, the first wave of which hit the United States in the spring of 2009, followed by a second, larger wave in the fall and winter; activity peaked in October and then quickly declined to below baseline levels by January 2010, but small numbers of cases were reported through the spring and summer of 2010. [16]
In addition, the effect of H1N1 influenza across the lifespan differed from that of typical influenza. Disease was more severe among people younger than 65 years than in nonpandemic influenza seasons, with significantly higher pediatric mortality and higher rates of hospitalizations in children and young adults. Of the 477 reported H1N1-associated deaths from April to August 2009, 36 were in children younger than 18 years; 67% of those children had one or more high-risk medical conditions. [16]
No cases of the highly pathogenic H5N1 influenza have been reported in humans or birds in the United States. Frequently updated information on H5N1 avian influenza cases and pandemic flu preparedness is available from the CDC. [17] Two case reports describe humans infected with another avian influenza virus, H7N2, one in Virginia in 2002 and the other in New York in 2003. The patients had no characteristic symptoms, but the first had positive serologic results and the second had mild respiratory symptoms.
As of 2021, 862 cases of avian influenza had been reported by the World Health Organization (WHO) worldwide, with 455 deaths. [12] Reporting from areas with poor access to health care may be limited to clinically severe cases; illness that does not fulfill WHO diagnostic criteria is not reported. [18]
Most cases have been in eastern Asia; some cases have been reported in Eastern Europe and North Africa. Underreporting has been a concern, particularly in China, but the prevailing attitude about the need to suspect, test, and report cases of avian influenza is growing. In 2013, cases were reported in Cambodia, Vietnam, China, Egypt, and Bangladesh.
In patients without comorbid disease who contract seasonal influenza, the prognosis is very good. However, some patients have a prolonged recovery time and remain weak and fatigued for weeks. Mortality from seasonal influenza is highest in infants and the elderly.
The prognosis for patients with avian influenza is related to the degree and duration of hypoxemia. Cases to date have exhibited a 60% mortality; however, Wang et al suggest that this may be an overestimate stemming from the underreporting of mild cases. [18]
The risk for mortality from avian influenza depends on the degree of respiratory disease rather than on the bacterial complications (pneumonia). Mortality is significantly lower among patients cared for in more-developed nations. Little evidence is available regarding the long-term effects of disease among survivors.
Diabetes increases the risk for severe flu-related illness. In a cohort study of 166,715 individuals in Manitoba, Canada, Lau and colleagues found that adults with diabetes were at significantly greater risk for serious illness related to influenza compared with those without diabetes; this justifies guideline recommendations for influenza vaccination in this population. After controlling for age, sex, socioeconomic status, location of residence, comorbidities, and vaccination, adults with diabetes had a significant increase (6%) in all-cause hospitalizations associated with influenza (P = .044). Only 16% of the patients with diabetes in the cohort and 7% of the patients without diabetes had been vaccinated. [19, 20]
Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006 Jan. 12(1):9-14. [QxMD MEDLINE Link].[Full Text].
Guharoy R, Gilroy SA, Noviasky JA, Ference J. West Nile virus infection. Am J Health Syst Pharm. 2004 Jun 15. 61(12):1235-41. [QxMD MEDLINE Link].
CDC. Seasonal Influenza (Flu): Guidance for Clinicians on the Use of RT-PCR and Other Molecular Assays for Diagnosis of Influenza Virus Infection. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/flu/professionals/diagnosis/molecular-assays.htm. Oct 21, 2019; Accessed: April 26, 2024.
Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005 Sep 29. 353 (13):1363-73. [QxMD MEDLINE Link].
Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A. 1993 May 1. 90(9):4171-5. [QxMD MEDLINE Link].[Full Text].
WHO. Influenza (Avian and other zoonotic). World Health Organization. Available athttps://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic). October 3, 2023; Accessed: April 26, 2024.
WHO. Leading health agencies outline updated terminology for pathogens that transmit through the air. World Health Organization. Available athttps://www.who.int/news/item/18-04-2024-leading-health-agencies-outline-updated-terminology-for-pathogens-that-transmit-through-the-air. April 18, 2024; Accessed: April 25, 2024.
Gu Y, Komiya N, Kamiya H, Yasui Y, Taniguchi K, Okabe N. Pandemic (H1N1) 2009 transmission during presymptomatic phase, Japan. Emerg Infect Dis. 2011 Sep. 17(9):1737-9. [QxMD MEDLINE Link].[Full Text].
Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010 Jul 7. CD001269. [QxMD MEDLINE Link].
World Health Organization Writing Group, Bell D, Nicoll A, et al. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis. 2006 Jan. 12 (1):81-7. [QxMD MEDLINE Link].[Full Text].
Auewarakul P, Suptawiwat O, Kongchanagul A, et al. An avian influenza H5N1 virus that binds to a human-type receptor. J Virol. 2007 Sep. 81(18):9950-5. [QxMD MEDLINE Link].[Full Text].
WHO. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2021. World Health Organization. Available athttps://www.who.int/publications/m/item/cumulative-number-of-confirmed-human-cases-for-avian-influenza-a(h5n1)-reported-to-who-2003-2021-15-april-2021. 15 Apr 2021; Accessed: April 26, 2024.
Matsuzaki Y, Abiko C, Mizuta K, et al. A nationwide epidemic of influenza C virus infection in Japan in 2004. J Clin Microbiol. 2007 Mar. 45(3):783-8. [QxMD MEDLINE Link].[Full Text].
WHO. Global Influenza Strategy 2019-2030. World Health Organization. Available athttps://www.who.int/publications/i/item/9789241515320. March 15, 2019; Accessed: April 26, 2024.
2023-2024 U.S. Flu Season: Preliminary Burden Estimates. Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/flu-burden/php/data-vis/2023-2024.html. 2024 Aug 05; Accessed: August 19, 2024.
CDC. 2020-21 Flu Season Summary FAQ. Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/flu/season/faq-flu-season-2020-2021.htm. October 25, 2021; Accessed: August 10, 2023.
CDC. Bird Flu Virus Infections in Human. Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/flu/avianflu/avian-in-humans.htm. May 4, 2022; Accessed: April 26, 2024.
Wang TT, Parides MK, Palese P. Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science. 2012 Mar 23. 335 (6075):1463. [QxMD MEDLINE Link].
Lau D, Eurich DT, Majumdar SR, Katz A, Johnson JA. Working-age adults with diabetes experience greater susceptibility to seasonal influenza: a population-based cohort study. Diabetologia. 2014 Apr. 57 (4):690-8. [QxMD MEDLINE Link].[Full Text].
Melville N. New Evidence: Diabetes Does Up Risk for Flu-Related Illness. Medscape [serial online]. Available athttps://www.medscape.com/viewarticle/819737. January 27, 2014; Accessed: April 26, 2024.
Steininger C, Popow-Kraupp T, Laferl H, et al. Acute encephalopathy associated with influenza A virus infection. Clin Infect Dis. 2003 Mar 1. 36(5):567-74. [QxMD MEDLINE Link].
Chertow DS, Memoli MJ. Bacterial coinfection in influenza: a grand rounds review. JAMA. 2013 Jan 16. 309(3):275-82. [QxMD MEDLINE Link].
Tasher D, Stein M, Simoes EA, Shohat T, Bromberg M, Somekh E. Invasive bacterial infections in relation to influenza outbreaks, 2006-2010. Clin Infect Dis. 2011 Dec. 53 (12):1199-207. [QxMD MEDLINE Link].
Waldeck F, Boroli F, Suh N, Wendel Garcia PD, Flury D, Notter J, et al. Influenza-associated aspergillosis in critically-ill patients-a retrospective bicentric cohort study. Eur J Clin Microbiol Infect Dis. 2020 Oct. 39 (10):1915-1923. [QxMD MEDLINE Link].
Kumar K, Guirgis M, Zieroth S, et al. Influenza myocarditis and myositis: case presentation and review of the literature. Can J Cardiol. 2011 Jul-Aug. 27(4):514-22. [QxMD MEDLINE Link].
Apisarnthanarak A, Erb S, Stephenson I, et al. Seroprevalence of anti-H5 antibody among Thai health care workers after exposure to avian influenza (H5N1) in a tertiary care center. Clin Infect Dis. 2005 Jan 15. 40(2):e16-8. [QxMD MEDLINE Link].
[Guideline] CDC. Interim Guidance on Testing, Specimen Collection, and Processing for Patients with Suspected Infection with Novel Influenza A Viruses with the Potential to Cause Severe Disease in Humans. Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/flu/avianflu/severe-potential.htm. June 14, 2023; Accessed: April 26, 2024.
[Guideline] WHO. Influenza: H5N1. World Health Organization. Available athttps://www.who.int/news-room/questions-and-answers/item/influenza-h5n1#:~:text=In%20most%20cases%2C%20avian%20influenza,be%20used%20in%20all%20cases.. 11 March 2012; Accessed: April 26, 2024.
WHO. H5N1 avian influenza: Timeline of major events. World Health Organization. Available athttps://www.cdc.gov/flu/avianflu/timeline/avian-timeline-2020s.htm#:~:text=In%20March%202024%2C%20HPAI%20H5N1,spread%20of%20H5N1%20bird%20flu.. December 4, 2014; Accessed: April 26, 2024.
CDC. Rapid Diagnostic Testing for Influenza: Information for Clinical Laboratory Directors. US Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/flu/professionals/diagnosis/rapidlab.htm#:~:text=Rapid%20influenza%20diagnostic%20tests%20(RIDTs)%20detect%20influenza%20viral%20antigens%20in,subtypes%20of%20influenza%20A%20viruses.. February 4, 2019; Accessed: April 26, 2024.
Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med. 2012 Apr 3. 156(7):500-11. [QxMD MEDLINE Link].
Landry ML. Diagnostic tests for influenza infection. Curr Opin Pediatr. 2011 Feb. 23(1):91-7. [QxMD MEDLINE Link].
Lowes R. New Flu Test Delivers Molecular Results in Under 15 Minutes. Medscape Medical News. Available athttps://www.medscape.com/viewarticle/826847. June 16, 2014; Accessed: April 26, 2024.
Haran JP, Buglione-Corbett R, Lu S. Cytokine markers as predictors of type of respiratory infection in patients during the influenza season. Am J Emerg Med. 2013 May. 31(5):816-21. [QxMD MEDLINE Link].
Oner AF, Bay A, Arslan S, et al. Avian influenza A (H5N1) infection in eastern Turkey in 2006. N Engl J Med. 2006 Nov 23. 355(21):2179-85. [QxMD MEDLINE Link].
Barclay L. FDA Clearance for Avian Influenza A Rapid Test. Medscape. Available athttps://www.medscape.com/viewarticle/590848. April 9, 2009; Accessed: April 26, 2024.
Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005 Sep 29. 353(13):1374-85. [QxMD MEDLINE Link].
Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis. 2005 Feb. 11(2):201-9. [QxMD MEDLINE Link].[Full Text].
Brown T. CDC Releases New H7N9 Testing Recommendations. Medscape [serial online]. Available athttps://www.medscape.com/viewarticle/805620. June 11, 2013; Accessed: April 26, 2024.
CDC. Archived – Asian Lineage Avian Influenza A(H7N9) Virus. Centers for Disease Control and Prevention (CDC). Available athttps://www.cdc.gov/flu/avianflu/h7n9-virus.htm. December 7, 2018-Archived; Accessed: April 26, 2024.
CDC. Prevent Seasonal Flu. Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/flu/prevent/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fprotect%2Fvaccine%2Findex.htm. December 19, 2022; Accessed: April 26, 2024.
[Guideline] Robinson CL, Romero JR, Kempe A, Pellegrini C, Szilagyi P. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2018. MMWR Morb Mortal Wkly Rep. 2018 Feb 9. 67 (5):156-157. [QxMD MEDLINE Link].[Full Text].
Use of Trivalent Influenza Vaccine for the 2024-2025 U.S. Influenza Season. US Food and Drug Administration. Available athttps://www.fda.gov/vaccines-blood-biologics/lot-release/use-trivalent-influenza-vaccines-2024-2025-us-influenza-season. 2024 Mar 03; Accessed: August 19, 2024.
CDC. Flu Vaccine and People with Egg Allergies. Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/flu/prevent/egg-allergies.htm. August 25, 2022; Accessed: April 26, 2024.
Lee V, Yap J, Cook AR, et al. Effectiveness of public health measures in mitigating pandemic influenza spread: a prospective sero-epidemiological cohort study. J Infect Dis. 2010 Nov 1. 202 (9):1319-26. [QxMD MEDLINE Link].
Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season. US Food & Drug Administration. Available athttps://www.fda.gov/vaccines-blood-biologics/influenza-vaccine-composition-2025-2026-us-influenza-season. 2025 Mar 13; Accessed: 2025 Aug 12.
Wodi AP, Issa AN, Moser CA, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2025. MMWR. January 16, 2025. 74(2):30-33. [Full Text].
Brown T. First Human Trial of Universal Flu Vaccine Underway. Medscape Medical News. Available athttps://www.medscape.com/viewarticle/911374. April 4, 2019; Accessed: April 26, 2024.
Lowes R. FDA Okays Novel Flu Vaccine Made Without Eggs, Viruses. Medscape Medical News. Available athttps://www.medscape.com/viewarticle/777773. January 16, 2013; Accessed: April 26, 2024.
Maternal and Infant Outcomes Among Severely Ill Pregnant and Postpartum Women with 2009 Pandemic Influenza A (H1N1) --- United States, April 2009--August 2010. MMWR Morb Mortal Wkly Rep. Sep 9 2011;60:1193-6. [QxMD MEDLINE Link].[Full Text].
Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vazquez M. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis. 2010 Dec 15. 51 (12):1355-61. [QxMD MEDLINE Link].
Brooks M. Trivalent Flu Vaccine Works in Pregnant Women. Medscape. Dec 13 2013. [Full Text].
Thompson MG, Li DK, Shifflett P, et al. Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010-2011 and 2011-2012 influenza seasons. Clin Infect Dis. 2013 Nov 26. [QxMD MEDLINE Link].
Influenza vaccination coverage among pregnant women--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep. 2013 Sep 27. 62(38):787-92. [QxMD MEDLINE Link].[Full Text].
Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009 Jul 15. 200 (2):172-80. [QxMD MEDLINE Link].
DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014 Aug 14. 371(7):635-45. [QxMD MEDLINE Link].
Garcia J. Influenza: high-dose vaccine decreases flu in older adults. Medscape Medical News. August 14, 2014. [Full Text].
Woods JA, Keylock KT, Lowder T, et al. Cardiovascular exercise training extends influenza vaccine seroprotection in sedentary older adults: the immune function intervention trial. J Am Geriatr Soc. 2009 Dec. 57 (12):2183-91. [QxMD MEDLINE Link].
Alsharifi M, Furuya Y, Bowden TR, et al. Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections. PLoS One. 2009. 4 (4):e5336. [QxMD MEDLINE Link].
MacMahon KL, Delaney LJ, Kullman G, Gibbins JD, Decker J, Kiefer MJ. Protecting poultry workers from exposure to avian influenza viruses. Public Health Rep. 2008 May-Jun. 123(3):316-22. [QxMD MEDLINE Link].[Full Text].
Gray GC, Baker WS. The importance of including swine and poultry workers in influenza vaccination programs. Clin Pharmacol Ther. 2007 Dec. 82 (6):638-41. [QxMD MEDLINE Link].
FDA. Flu Vaccines. US Food and Drug Administration. Available athttps://www.fda.gov/vaccines-blood-biologics/vaccines/flu-vaccines. February 8, 2023; Accessed: April 26, 2024.
Alsharifi M, Furuya Y, Bowden TR, Lobigs M, Koskinen A, Regner M, et al. Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections. PLoS One. 2009. 4 (4):e5336. [QxMD MEDLINE Link].
Belshe RB, Frey SE, Graham I, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis. 2011 Mar 1. 203(5):666-73. [QxMD MEDLINE Link].[Full Text].
Lowes R. FDA Approves First Adjuvanted Vaccine for H5N1 Bird Flu. Medscape Medical News. Available athttps://www.medscape.com/viewarticle/814914. Nov 22 2013; Accessed: April 26, 2024.
Gensheimer KF, Meltzer MI, Postema AS, Strikas RA. Influenza pandemic preparedness. Emerg Infect Dis. 2003 Dec. 9(12):1645-8. [QxMD MEDLINE Link].[Full Text].
CDC. Healthy Habits to Help Protect Against Flu. Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/flu/prevent/actions-prevent-flu.htm#:~:text=Clean%20and%20disinfect%20frequently%20touched,fluids%2C%20and%20eat%20nutritious%20food.. August 26, 2021; Accessed: April 26, 2024.
[Guideline] CDC. Influenza Antiviral Medications: Summary for Clinicians. Centers for Disease Control and Prevention (CDC). Available athttps://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. 2018 Dec 27; Accessed: April 26, 2024.
[Guideline] Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5. 68 (6):e1-e47. [QxMD MEDLINE Link].[Full Text].
Kohno S, Kida H, Mizuguchi M, Shimada J, S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010 Nov. 54 (11):4568-74. [QxMD MEDLINE Link].[Full Text].
Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis. 2010 Oct 15. 202 (8):1154-60. [QxMD MEDLINE Link].
Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis. 2013 Feb 15. 207(4):553-63. [QxMD MEDLINE Link].[Full Text].
Lam J, Nikhanj N, Ngab T, et al. Severe cases of pandemic H1N1 pneumonia and respiratory failure requiring intensive care. J Intensive Care Med. 2011 Sep-Oct. 26 (5):318-25. [QxMD MEDLINE Link].
CDC. Centers for Disease Control and Prevention. Seasonal Influenza (Flu): Antiviral Drugs. US Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/flu/professionals/antivirals/index.htm. December 19, 2022; Accessed: April 26, 2024.
Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018 Sep 6. 379 (10):913-923. [QxMD MEDLINE Link].
Baker J, Block SL, Matharu B, Burleigh Macutkiewicz L, Wildum S, Dimonaco S, et al. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J. 2020 Aug. 39 (8):700-705. [QxMD MEDLINE Link].[Full Text].
Ikematsu H, Hayden FG, Kawaguchi K, Kinoshita M, de Jong MD, Lee N, et al. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. N Engl J Med. 2020 Jul 23. 383 (4):309-320. [QxMD MEDLINE Link].[Full Text].
Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999 Oct 28. 341 (18):1336-43. [QxMD MEDLINE Link].
Aoki FY, Macleod MD, Paggiaro P, et al; IMPACT Study Group. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003 Jan. 51 (1):123-9. [QxMD MEDLINE Link].
Hill G, Cihlar T, Oo C, et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan. 30 (1):13-9. [QxMD MEDLINE Link].
Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999 Oct 6. 282 (13):1240-6. [QxMD MEDLINE Link].
Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000 Feb 23. 283 (8):1016-24. [QxMD MEDLINE Link].
Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis. 2010 Oct 15. 51 (8):887-94. [QxMD MEDLINE Link].
Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012 Jan 18. 1:CD008965. [QxMD MEDLINE Link].
Hayden FG, Gubareva LV, Monto AS, et al; Zanamivir Family Study Group. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med. 2000 Nov 2. 343 (18):1282-9. [QxMD MEDLINE Link].
Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet. 1998 Dec 12. 352 (9144):1877-81. [QxMD MEDLINE Link].
Chamni S, De-Eknamkul W. Recent progress and challenges in the discovery of new neuraminidase inhibitors. Expert Opin Ther Pat. 2013 Apr. 23(4):409-23. [QxMD MEDLINE Link].
Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y, MARVEL Study Group. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010 Nov 15. 51 (10):1167-75. [QxMD MEDLINE Link].
Brooks M. FDA Okays 4-Strain Seasonal Influenza Vaccine. Medscape Medical News. Available athttps://www.medscape.com/viewarticle/776271?src=nl_newsalert. December 17, 2012; Accessed: April 26, 2024.
https://www.fda.gov/vaccines-blood-biologics/vaccines/flumist-quadrivalent. US Food and Drug Administration. Available athttps://www.fda.gov/vaccines-blood-biologics/vaccines/flumist-quadrivalent. 07/06/2023; Accessed: April 26, 2024.
Brown T. Nasal Flu Vaccine Back on CDC List of Recommended Vaccines. Medscape Medical News. Available athttps://www.medscape.com/viewarticle/892970. 2018 Feb 22; Accessed: April 26, 2024.
Jackson ML, Chung JR, Jackson LA, Phillips CH, Benoit J, Monto AS, et al. Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season. N Engl J Med. 2017 Aug 10. 377 (6):534-543. [QxMD MEDLINE Link].
CDC. ACIP votes down use of LAIV for 2016-2017 flu season. Centers for Disease Control and Prevention (CDC). Available athttps://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html. 2016 Jun 22; Accessed: April 26, 2024.
Brown T. Influenza Continues Unabated in US, Deaths in the Thousands. Medscape Medical News. Available athttps://www.medscape.com/viewarticle/923428. January 6, 2020; Accessed: April 26, 2024.
CDC. Interim Guidance for Specimen Collection, Processing, and Testing for Patients with Suspected Infection with Novel Influenza A Viruses Associated with Severe Disease in Humans. Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/flu/avianflu/h7n9/specimen-collection.htm. January 27, 2014; Accessed: April 26, 2024.
Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for Prevention and Control of Influenza in Children, 2021-2022. Pediatrics. 2021 Oct. 146 (4):[QxMD MEDLINE Link].[Full Text].
[Guideline] WHO. Clinical practice guidelines for influenza. World Health Organization. Available athttps://iris.who.int/bitstream/handle/10665/378872/9789240097759-eng.pdf?sequence=1. September 12, 2024; Accessed: September 13, 2024.
US FDA. Influenza Vaccine Composition for the 2026-2027 U.S. Influenza Season. U.S. Food & Drug Administration. Available athttps://www.fda.gov/vaccines-blood-biologics/vaccines/influenza-vaccine-composition-2026-2027-us-influenza-season. 13 Mar 2026; Accessed: 10 Apr 2026.